This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global age-related macular degeneration (AMD) drugs market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
Secondary Research
The secondary sources referred to for this research study include publications from government sources. Corporate and regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; white papers; press releases; and trade, business, and professional associations, were also used as secondary sources for this research report. Secondary data was collected and analyzed to arrive at the overall size of the global Age-Related Macular Degeneration (AMD) drugs market, which was validated through primary research.
Primary Research
Extensive primary research was conducted after acquiring basic knowledge about the global Age-Related Macular Degeneration (AMD) drugs market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as ophthalmologists, and personnel from specialty centers and long-term care facilities, along with experts from the supply side, such as C-level and D-level executives, product managers, marketing & sales managers of key manufacturers, distributors, and channel partners. These interviews were conducted across six major regions, including the Asia Pacific, North America, Europe, Latin America, the Middle East, and Africa. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The global size of the market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the age-related macular degeneration (AMD) drugs market and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
-
The key players in the industry and market have been identified through extensive primary and secondary research.
-
The revenues generated from the age-related macular degeneration (AMD) drugs business of leading players have been determined through primary and secondary research.
-
All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
To know about the assumptions considered for the study, Request for Free Sample Report
Data Triangulation
After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.
Market Definition
Age-related macular degeneration (AMD) is a progressive eye condition that primarily affects individuals over the age of 50, leading to the deterioration of central vision due to damage to the macula, the part of the retina responsible for sharp, detailed vision. AMD is classified into two main types: dry (non-neovascular) and wet (neovascular). Dry AMD involves the gradual breakdown of light-sensitive cells in the macula, often indicated by the presence of drusen (yellow deposits). Wet AMD is characterized by the growth of abnormal blood vessels beneath the retina, which leak fluid or blood, causing rapid vision loss. This market includes the market for marketed biologics and biosimilars along with Phase 3 molecules for the treatment of AMD.
Stakeholders
-
Pharmaceutical & biotechnology companies
-
Hospitals
-
Specialty centers
-
Long-term care facilities
-
Academic researchers and government research organizations
-
Private research institutes
-
Contract manufacturing organizations (CMOs)
-
Contract research organizations (CROs)
-
Venture capitalists
Report Objectives
-
To define, describe, and forecast the global age-related macular degeneration (AMD) drugs market based on product, molecule, type of AMD, approval type, end user, and region
-
To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, opportunities, and challenges)
-
To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
-
To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
-
To forecast the size of the market segments with respect to six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa
-
To profile the key players and comprehensively analyze their product & service portfolios, market positions, and core competencies
-
To track and analyze competitive developments such as acquisitions, product/ service launches, expansions, agreements, partnerships, and collaborations in the market
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Geographical Analysis
-
Further breakdown of the Rest of Europe Age-related macular degeneration (AMD) drugs market, by country
-
Further breakdown of the Rest of Asia Pacific Age-related macular degeneration (AMD) drugs market, by country
-
Further breakdown of the Rest of Latin America and Middle East & Africa Age-related macular degeneration (AMD) drugs market, by country
Company Information
-
Detailed analysis and profiling of additional market players (up to five)
Growth opportunities and latent adjacency in Age-related Macular Degeneration (AMD) Drugs Market